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Because of its advantageous depth-dose relationship, proton radiotherapy is an emerging treatment
modality for patients with liver cancer. Although the proton dose distribution conforms to the target,
healthy tissues throughout the body receive low doses of stray radiation, particularly neutrons that
originate in the treatment unit or in the patient. The aim of this study was to calculate the effective
dose from stray radiation and estimate the corresponding risk of second cancer fatality for a patient
receiving proton beam therapy for liver cancer. Effective dose from stray radiation was calculated
using detailed Monte Carlo simulations of a double-scattering proton therapy treatment unit and a
voxelized human phantom. The treatment plan and phantom were based on CT images of an actual
adult patient diagnosed with primary hepatocellular carcinoma. For a prescribed dose of 60 Gy to
the clinical target volume, the effective dose from stray radiation was 370 mSv; 61% of this dose
was from neutrons originating outside of the patient while the remaining 39% was from neutrons
originating within the patient. The excess lifetime risk of fatal second cancer corresponding to the
total effective dose from stray radiation was 1.2%. The results of this study establish a baseline
estimate of the stray radiation dose and corresponding risk for an adult patient undergoing proton
radiotherapy for liver cancer and provide new evidence to corroborate the suitability of proton beam
therapy for the treatment of liver tumors.
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I. Introduction
Proton beam radiotherapy is an emerging treatment modality for patients with liver cancer
because the unique physical characteristics of protons allow dose escalation to the clinical
target volume (CTV) while sparing the nearby normal tissue. In photon or neutron therapy the
maximum dose for each field is deposited near the surface of the patient, followed by a long
exponential falloff of dose with depth along the beam path. In contrast, the maximum dose
from a proton field is deposited near the end of a finite range, followed by a sharp and almost
complete decrease in dose, virtually eliminating exit dose. This gives proton therapy a
dosimetric advantage over photon radiotherapy in the sparing of nearby healthy tissues and
organs. This is especially important for tumors that are near or within radiosensitive organs at
risk for radiation carcinogenesis or toxicity. However, in the process of delivering a proton
c
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field that conforms to the CTV, stray radiation, mainly in the form of photons and neutrons, is
produced, which can be detrimental to the patient and has no therapeutic benefit.1-13 Exposure
to neutrons, whether emanating from the treatment unit (“external neutrons”) or inside the
patient (“internal neutrons”), is of particular concern because neutrons are the predominant
contributors to the effective dose from stray radiation. Furthermore, the relative biological
effectiveness of neutrons for carcinogenesis is known to be high, although the exact value
remains uncertain.14 To our knowledge, the current study is the first to investigate exposure
to neutrons for patients receiving proton therapy for liver cancer.
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The rationale for treating liver cancer with protons is largely based on the need to spare as
much of the healthy liver as possible. Radiotherapy of a partial liver volume is noninvasive,
may slow the progression of the disease until resection or transplantation is viable, and is
potentially curative. However, radiotherapy to the entire liver is usually toxic, limiting the dose
that can be delivered and requiring the use of precise beams that can focus the radiation dose
to a partial volume. Treatments with charged particle beams have been generally encouraging,
and the limited clinical outcomes suggest that it may be possible to significantly improve tumor
control rates.15 Proton therapy for liver cancer has permitted dose escalation to the CTV without
leading to dose-limiting toxicity, suggesting that this modality has potential as a curative
treatment for liver cancer.16 However, because of the risk for toxicity and second cancers—
especially in the remaining liver volume, but also throughout the body—a better understanding
of the stray neutron doses is needed.
The aim of this study, therefore, was to calculate the effective dose from stray radiation to a
patient undergoing proton radiotherapy for liver cancer. To do this, we performed Monte Carlo
simulations quantifying the radiation doses to various organs and tissues throughout the body.
The geometric model used in the simulation consisted of a detailed double-scattering proton
therapy treatment unit and a voxelized phantom based on computed tomography (CT) images
of a patient diagnosed with liver cancer. We also estimated the risk of developing a second
fatal cancer using risk coefficients from the literature and the calculated doses from the
simulations.

II. Methods
II.A. Monte Carlo Model
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In this study, we simulated a proton treatment for a large 59-year-old man diagnosed at our
institution with primary hepatocellular carcinoma. The patient had undergone free-breathing
CT imaging as part of treatment planning; using those same images, we created a proton
treatment plan using a commercial treatment planning system (Eclipse Proton Planning; Varian
Medical Systems, Inc., Palo Alto, CA).17 The prescribed dose to 100% of the CTV (that is, the
gross tumor volume plus margins) was 60 Gy. The plan was optimized for two proton fields,
both having a posterior oblique beam configuration and passing through the treatment couch.
One posterior oblique field (PO1) was delivered with a gantry rotation of 220°; a couch rotation
of 45°; a proton beam energy of 225 MeV at the entrance of the treatment head, corresponding
to a penetration range in the patient of 20.1 cm; a spread-out Bragg peak (SOBP) width of 14
cm; and a nominal gap of 23 cm between the distal component of the treatment unit, i.e., edge
of the range compensator, and the proximal surface of the patient. The other posterior oblique
field (PO2) was delivered with a gantry rotation of 135°; a couch rotation of -40°; a proton
beam energy of 250 MeV at the entrance of the treatment head, corresponding to a penetration
range in the patient of 25.0 cm; an SOBP width of 13 cm; and a nominal gap of 21 cm. Beam
modifiers included a range-modulator wheel, scattering foil, range shifter, field-defining
collimator, and range compensator.17 The range compensator and field-defining collimator
were carried within a snout that provided shielding and allowed for the shifting of the devices
along the beam path. An intermediate size of the three available snouts was used for both
AIP Conf Proc. Author manuscript; available in PMC 2010 September 21.
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treatment fields (25-cm-diameter uncollimated field size, accommodating up to an 18 × 18
cm2 collimated field). The field-defining collimator for both fields was 6 cm thick and made
of brass.
Monte Carlo simulations were performed using the Monte Carlo N-Particle extended
(MCNPX) code (version 2.6b)18 with parallel computing methods. The suitability of the
MCNPX code for simulating therapeutic absorbed dose distributions and secondary neutrons
associated with proton therapy has been previously established.2-4,17,19-26 The Monte Carlo
model of the proton treatment unit included a proton source, the beam-modifying devices, the
structural and housing components, and various static collimators.8,17 A voxelized phantom
representing the patient was based on the actual CT images for the patient, which included
slices from the thighs to the top of the head. The Hounsfield unit value in each 4 mm × 4 mm
× 5 mm voxel was converted to a mass density and a material composition.27
II.B. Dosimetric Calculations
The effective dose from neutrons, E, was calculated as

(1)
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where wT was the tissue (T) weighting factor and HT was the equivalent dose to organs and
tissues.28 The wT values were taken from the International Commission on Radiological
Protection (ICRP) Publication 60.29 HT was calculated separately for internal neutrons and
external neutrons for each treatment field as the product of the radiation weighting factor,
wR, and the mean absorbed dose for each organ or tissue, DT, or
(2)

The wR values for external neutrons were determined separately for each treatment field based
on the calculated neutron spectral fluence incident upon the patient, following the
recommendations in ICRP Publication 92.28 The wR values for internal neutrons were
estimated based on the calculations of Zheng et al.7 Using estimated values of wR for internal
neutrons introduced less than 10% uncertainty in E. DT was calculated as the mass-weighted
average of the absorbed dose of all voxels within the organ or tissue.
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To calculate absorbed dose in each voxel per source particle, Dv/sp, (in Gy sp-1), we performed
separate simulations for therapeutic protons, external neutrons, and internal neutrons for each
treatment field. For the external neutron simulations, neutrons and protons were tracked
throughout the entire geometry except that all proton trajectories were terminated immediately
upstream of the patient by a proton-stopping plane (imp:h=0,n>0), and Dv/sp was calculated
throughout the patient using a type 3 mesh tally (keyword “total”). For the internal neutron
simulations, neutrons were only tracked within the geometric model of the patient (outside
patient, imp:h>0,n=0; inside patient, imp:h,n>0), i.e., external neutrons were not allowed to
contribute to absorbed dose, and a more complex procedure was used for calculating Dv/sp
from internal neutrons so that the contribution from recoil protons was included. For the
therapeutic proton simulations, only protons were tracked throughout the model and the massaveraged absorbed dose per source particle in the CTV, DT=CTV/sp, was calculated for each
treatment beam. The reciprocal of DT=CTV/sp, that is, the number of protons per Gy in the
CTV, was then used to normalize Dv/sp separately for each treatment field, resulting in E (in
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mSv Gy-1), HT (in mSv Gy-1), and DT (in mGy Gy-1). E and HT values from individual treatment
fields were combined to yield the corresponding quantities for the entire course of 60 Gy.
Detailed methods for calculating these quantities have been described elsewhere.30
To achieve reasonable statistical uncertainties in DT, 4 × 108, 4 × 108, and 2 × 108, source
particle histories were tracked for the external neutron, internal neutron, and therapeutic proton
simulations, respectively. Statistical uncertainties were based on the coefficients of variation
reported by the MCNPX code at the 68% confidence interval. The uncertainties in the wT and
wR values for internal neutrons were taken as zero.

III. Results
The values of E for each field are listed in Table 1. As shown, E for the entire treatment was
370 mSv (i.e., E/DT=CTV was 6.17 mSv Gy-1). The contribution of PO2, which had the higher
initial proton energy, was 61% of the total E. The values of E from external and internal
neutrons were 227 mSv (61% of total E) and 143 mSv (39% of total E), respectively, for the
two-field treatment.
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Table 2 lists the HT values for the two posterior oblique fields for the 60-Gy treatment. HT was
larger for PO2 than for PO1 for each organ and tissue. Also listed are the sums of HT for the
two fields and the sums of HTwT, the proportion of the effective dose in each organ. The organs
and tissues that received the greatest proportions of the effective dose were the lungs (18%),
stomach (15%), liver (14%), red bone marrow (12%), colon (11%), and esophagus (8%). The
distributions of absorbed dose from therapeutic protons and equivalent dose from neutrons
throughout the patient are illustrated in Figure 1. The maximum mean equivalent dose to an
organ or tissue from stray radiation was 1.03 Sv to the entire liver.
The calculated mean values of wR for external neutrons were 8.892 ± 0.008 for PO1 and 8.944
± 0.005 for PO2. The estimated value of wR for internal neutrons was 9.6 for both fields. The
total computing time for all simulations in this study was 4.4 cpu·years using parallel processing
on 2.6-GHz, 64-bit microprocessors (AMD Opteron; Advanced Micro Devices, Inc.,
Sunnyvale, CA).

IV. Discussion
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We calculated the effective dose from stray radiation, E, in a simulated treatment for a 59-yearold man receiving proton radiotherapy for liver cancer. The Monte Carlo calculations were
based on a detailed model of a double-scattering proton therapy treatment unit and CT images
from an actual patient for a complete 60-Gy proton treatment to the CTV. The total E was 370
mSv; 61% of E was from external neutrons, and 39% of E was from internal neutrons.
The value of the total E (370 mSv) was equivalent to the effective dose associated with
approximately 20 whole-body CT scans. The National Council on Radiation Protection and
Measurements has suggested that each Sv of low-dose and low-dose-rate exposure increases
the fatal cancer risk by 3.2% for middle-aged men in general.31 Thus, for a population of
middle-aged men receiving the calculated total E, the corresponding excess attributable
lifetime risk of a second cancer fatality would be approximately 1.2%. That is, about 12 of
every 1000 middle-aged men treated in this way would die from second cancers caused by
neutrons. Although this risk is small compared with the benefits of the radiotherapy, it is not
negligible; methods to reduce the risk from neutrons emanating from the treatment unit are
being explored.30,32 Exposure to neutrons generated within the patient cannot be avoided.
However, exposure to external neutrons may be mitigated through enhancements to the
treatment unit.
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In this study, we assumed a 60-Gy treatment to account for the possibility of future dose
escalation. In the actual treatment plan, a dose of 60 cobalt Gray equivalent was prescribed,
which corresponds to a 55-Gy proton treatment in current clinical practice.
Today liver cancer remains a deadly disease; improved treatment strategies are urgently
needed. Proton radiotherapy provides a dosimetric advantage in that less healthy tissue in the
liver is exposed, which introduces the possibility of escalating the dose to the diseased portion
of the liver. Importantly, the results of this study clearly reveal the risks related to stray radiation
are small compared to the benefits of proton radiotherapy. This is particularly relevant for
hepatocellular carcinoma patients who choose proton radiotherapy as a bridge to liver
transplantation—a scenario where treatment outcomes are excellent (up to 70% 5-year survival
rates) and the likelihood of second malignancies after transplantation is higher than among
patients undergoing non-transplant treatments (secondary to immunosuppression to prevent
graft rejection). In summary, stray radiation should not be considered an obstacle to developing
proton treatments for liver cancer.
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FIGURE 1.

Absorbed dose from therapeutic protons in Gy (a) and equivalent dose from neutrons in Sv (b)
shown in planes that intersect the isocenter. The CTV is delineated in bright green.
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Effective dose from neutrons, E, for posterior oblique proton treatment fields PO1 and PO2. The effective dose
is further broken down into contributions from external and internal neutrons.
E (mSv)
Field

External

Internal

Total

PO1

81

63

144

PO2

146

80

226

Total

227

143

370

NIH-PA Author Manuscript
NIH-PA Author Manuscript
AIP Conf Proc. Author manuscript; available in PMC 2010 September 21.

NIH-PA Author Manuscript

NIH-PA Author Manuscript
0.12
0.12
0.12
0.12
0.05
0.05
0.05
0.05
0.05
0.01
0.01
0.05

Colon

Lungs

Stomach

Bladder

Breasts

Liver

Esophagus

Thyroid

Skin

Bone surface

Remainder

0.20

Gonads

Red bone marrow

wT

Organ or tissue

137

116

138

90

220

458

100

66

190

199

143

131

41

HT(PO1)
(mSv)

224

219

225

173

394

567

165

98

257

368

191

255

61

HT(PO2)
(mSv)

361

335

363

263

614

1025

265

163

447

568

333

385

102

HT
(mSv)

0.04%

0.09%

0.04%

1.65%

0.79%

0.13%

3.02%

1.63%

0.41%

0.45%

0.20%

0.16%

2.90%

σ(HT)/HT

18.0

3.4

3.6

13.1

30.7

51.3

13.3

8.2

53.6

68.1

40.0

46.2

20.3

HTwT
(mSv)

Equivalent dose in organs and tissues from neutrons, HT, for a 60-Gy treatment. HT is separated into contributions from treatment fields PO1 and PO2.
Statistical uncertainty, σ(HT), is listed in terms of percentage of HT. Also listed is the proportion of effective dose from neutrons, HTwT, in each organ or
tissue. wT is the tissue weighting factor for effective dose.
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